<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34615818</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7235</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>61</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Internal medicine (Tokyo, Japan)</Title>
          <ISOAbbreviation>Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab.</ArticleTitle>
        <Pagination>
          <StartPage>1265</StartPage>
          <EndPage>1270</EndPage>
          <MedlinePgn>1265-1270</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.7674-21</ELocationID>
        <Abstract>
          <AbstractText>A 49-year-old Japanese man with a 2-month history of a fever, headache, and bilateral conjunctival hyperemia was admitted. His condition fulfilled the giant cell arteritis classification criteria (new headache, temporal artery tenderness, elevated ESR) and atypical Cogan's syndrome (CS) with scleritis and sensorineural hearing loss (SNHL). The interleukin (IL)-6 serum level was extremely high. Two weeks after his insufficient response of SNHL and scleritis to oral prednisolone, we administered tocilizumab (TCZ); rapid improvements in scleritis and SNHL occurred. Early IL-6 target therapy can help prevent irreversible CS-induced sensory organ damage.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hara</LastName>
            <ForeName>Kazusato</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Umeda</LastName>
            <ForeName>Masataka</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Education Development Center, Nagasaki University Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segawa</LastName>
            <ForeName>Keiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akagi</LastName>
            <ForeName>Midori</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Endo</LastName>
            <ForeName>Yushiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koga</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawashiri</LastName>
            <ForeName>Shin-Ya</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ichinose</LastName>
            <ForeName>Kunihiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Hideki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maeda</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawakami</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Intern Med</MedlineTA>
        <NlmUniqueID>9204241</NlmUniqueID>
        <ISSNLinking>0918-2918</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I031V2H011</RegistryNumber>
          <NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537423">Apraxia, oculomotor, Cogan type</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001072" MajorTopicYN="N">Apraxias</DescriptorName>
          <QualifierName UI="Q000151" MajorTopicYN="N">congenital</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055952" MajorTopicYN="Y">Cogan Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013700" MajorTopicYN="Y">Giant Cell Arteritis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006319" MajorTopicYN="Y">Hearing Loss, Sensorineural</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007634" MajorTopicYN="Y">Keratitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015423" MajorTopicYN="Y">Scleritis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cogan's syndrome</Keyword>
        <Keyword MajorTopicYN="N">giant cell arteritis</Keyword>
        <Keyword MajorTopicYN="N">interleukin-6</Keyword>
        <Keyword MajorTopicYN="N">tocilizumab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34615818</ArticleId>
        <ArticleId IdType="doi">10.2169/internalmedicine.7674-21</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
